Analyst Price Target is $15.00
▲ +297.88% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for PhaseBio Pharmaceuticals in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 297.88% upside from the last price of $3.77.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in PhaseBio Pharmaceuticals. This Buy consensus rating has held steady for over two years.
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Malvern, PA.